Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Brian Bello

Psychiatry Long Beach, CA Medical Doctor

NPI 1902234651 CMS profile 388664

1045 Atlantic Ave Ste 608, Long Beach, CA 90813

Open in the dashboard

General payments

$7,567

406 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Brian Bello of Long Beach, CA is reported in the CMS Open Payments database as having received $7,567 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $220 9
2023 General $124 4
2022 General $2,183 124
2021 General $2,953 162
2020 General $1,591 82
2019 General $495 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Bello
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Brian Bello were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Brian Bello Psychiatry median Middle half National median
2019 $495 $184 $59–$605 $163
2020 $1,591 $119 $36–$372 $114
2021 $2,953 $143 $43–$576 $132
2022 $2,183 $153 $50–$590 $149
2023 $124 $170 $56–$651 $160
2024 $220 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alkermes, Inc. $1,069 54 payments
  2. Sunovion Pharmaceuticals Inc. $886 55 payments
  3. Otsuka America Pharmaceutical, Inc. $790 41 payments
  4. Teva Pharmaceuticals USA, Inc. $744 45 payments
  5. ITI, Inc. $696 37 payments
  6. Vanda Pharmaceuticals Inc. $590 28 payments
  7. Supernus Pharmaceuticals, Inc. $425 23 payments
  8. Neurocrine Biosciences, Inc. $410 21 payments
  9. Lundbeck LLC $334 17 payments
  10. Janssen Pharmaceuticals, Inc $304 13 payments
  11. Other $1,318 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,516 404 payments
  2. Education $50 2 payments
Products named General payments · program years 2019–2024
  1. ARISTADA INITIO $1,009 50 payments
  2. ARISTADA Cns $1,009 50 payments
  3. ARISTADA Cns $1,009 50 payments
  4. LATUDA $886 55 payments
  5. AUSTEDO $744 45 payments
  6. CAPLYTA $696 37 payments
  7. REXULTI $636 33 payments
  8. HETLIOZ $590 28 payments
  9. FANAPT $590 28 payments
  10. ARISTADA Cns $571 27 payments
  11. Other $4,877 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record